Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.6
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 30305722
Chong PSY, et al. (2018) Non-canonical activation of β-catenin by PRL-3 phosphatase in acute myeloid leukemia. Oncogene 30305722
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

S88-p - LEO1 (human)
Modsite: sERSDNRsEAsERSD SwissProt Entrez-Gene
Orthologous residues
LEO1 (human): S88‑p, LEO1 (mouse): S88‑p, LEO1 (rat): S88‑p
Characterization
Methods used to characterize site in vivo immunoprecipitation, mass spectrometry, mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  leukemia, acute myelogenous leukemia, acute erythroid leukemias, including erythroleukemia (M6a) and very rare pure erythroid leukemia (M6b)
Relevant cell lines - cell types - tissues:  E.coli (bacterial), HEK293T (epithelial), HEL (erythroid), Molm 14 (myeloid), OCI/AML2 (myeloid), TF-1 (erythroid)
Cellular systems studied:  cell lines
Species studied:  bacteria, human
Enzymes shown to modify site in vitro
Type Enzyme
PHOSPHATASE PTP4A3 (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
PHOSPHATASE PTP4A3 (human) co-immunoprecipitation, microscopy-colocalization, siRNA inhibition of enzyme, transfection of wild-type enzyme, transfection of inactive enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
siRNA increase PRL3 siRNA
Downstream Regulation
Effect of modification (function):  intracellular localization, molecular association, regulation
Effect of modification (process):  apoptosis, induced, carcinogenesis, inhibited, cell growth, inhibited, signaling pathway regulation, transcription, inhibited
Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
CTNNB1 (human) Disrupts intracellular localization co-immunoprecipitation

S91-p - LEO1 (human)
Modsite: SDNRsEAsERSDHED SwissProt Entrez-Gene
Orthologous residues
LEO1 (human): S91‑p, LEO1 (mouse): S91‑p, LEO1 (rat): S91‑p
Characterization
Methods used to characterize site in vivo immunoprecipitation, mass spectrometry, mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  leukemia, acute myelogenous leukemia, acute erythroid leukemias, including erythroleukemia (M6a) and very rare pure erythroid leukemia (M6b)
Relevant cell lines - cell types - tissues:  E.coli (bacterial), HEK293T (epithelial), HEL (erythroid), Molm 14 (myeloid), OCI/AML2 (myeloid), TF-1 (erythroid)
Cellular systems studied:  cell lines
Species studied:  bacteria, human
Enzymes shown to modify site in vitro
Type Enzyme
PHOSPHATASE PTP4A3 (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
PHOSPHATASE PTP4A3 (human) co-immunoprecipitation, microscopy-colocalization, siRNA inhibition of enzyme, transfection of wild-type enzyme, transfection of inactive enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
siRNA increase PRL3 siRNA
Downstream Regulation
Effect of modification (function):  intracellular localization, molecular association, regulation
Effect of modification (process):  apoptosis, induced, carcinogenesis, inhibited, cell growth, inhibited, signaling pathway regulation, transcription, inhibited
Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
CTNNB1 (human) Disrupts intracellular localization carcinogenesis, induced, signaling pathway regulation, cell growth, induced, transcription, induced, apoptosis, inhibited co-immunoprecipitation

S110-p - LEO1 (human)
Modsite: DVDQHsGsEAPNDDE SwissProt Entrez-Gene
Orthologous residues
LEO1 (human): S110‑p, LEO1 (mouse): S110‑p, LEO1 (rat): S111‑p
Characterization
Methods used to characterize site in vivo immunoprecipitation, mass spectrometry, mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  leukemia, acute myelogenous leukemia, acute erythroid leukemias, including erythroleukemia (M6a) and very rare pure erythroid leukemia (M6b)
Relevant cell lines - cell types - tissues:  E.coli (bacterial), HEK293T (epithelial), HEL (erythroid), Molm 14 (myeloid), OCI/AML2 (myeloid), TF-1 (erythroid)
Cellular systems studied:  cell lines
Species studied:  bacteria, human
Enzymes shown to modify site in vitro
Type Enzyme
PHOSPHATASE PTP4A3 (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
PHOSPHATASE PTP4A3 (human) co-immunoprecipitation, microscopy-colocalization, siRNA inhibition of enzyme, transfection of wild-type enzyme, transfection of inactive enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
siRNA increase PRL3 siRNA
Downstream Regulation
Effect of modification (function):  intracellular localization, molecular association, regulation
Effect of modification (process):  apoptosis, induced, carcinogenesis, inhibited, cell growth, inhibited, signaling pathway regulation, transcription, inhibited
Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
CTNNB1 (human) Disrupts intracellular localization co-immunoprecipitation